ArticleStatistics in medicine2026
Two-Step Error-Controlling Classifiers With Application to Cost-Effective Disease Diagnosis.
Article in Statistics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Accurate classifiers that use novel biomarkers and readily available predictors significantly enhance decision-making in various clinical scenarios, such as assessing the need for biopsies in cancer diagnosis. When classification performance is limited, a decision framework can be applied to rule in or rule out invasive diagnostic procedures while incorporating a neutral zone for indeterminate classifications. Building on this framework, we propose a new family of two-step classifiers that selectively use costly biomarker testing for a targeted subset of individuals undergoing multiple evaluations. The optimal solution expands upon the Neyman-Pearson Lemma, highlighting a vital trade-off between the costs of expensive biomarker measurements and improving classification performance while minimizing uncertainty in the decision process. We demonstrate the practical utility of our approach through a biomarker study focused on prostate cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.